Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 13 December 2016
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
Issued:
13 December 2016, London, UK - LSE Announcement
GSK announces intention to appoint Deloitte LLP as
Auditor
GSK today announces it intends to appoint Deloitte LLP ("Deloitte")
as its auditor with effect from the accounting year ending 31
December 2018.
This follows a competitive audit tender process overseen by an
Executive Steering Committee of GSK's Audit & Risk Committee
chaired by Judy Lewent, which culminated in a recommendation that
was approved by the Board.
The current auditor PricewaterhouseCoopers LLP ("PwC") will
continue in their role and undertake the audit of GSK until the
year ending 31 December 2017, subject to reappointment by
shareholders at GSK's 2017 Annual General Meeting. The appointment
of Deloitte will be recommended to GSK's shareholders for approval
at GSK's 2018 Annual General Meeting.
Judy Lewent, Chairman of GSK's Audit & Risk Committee,
said: "I am pleased that having
conducted a, thorough, open and transparent process, the Audit
& Risk Committee has concluded the audit tender. We would
like to thank PwC for their significant contribution as GSK's
auditor since the formation of GSK in 2001 and look forward to
working with Deloitte in the future."
GSK - one of the world's leading research-based
pharmaceutical and healthcare companies - is committed to improving
the quality of human life by enabling people to do more, feel
better and live longer. For further information please
visit www.gsk.com.
|
GSK enquiries:
|
|
|
|
|
UK
Media enquiries:
|
David
Mawdsley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
|
|
US
Media enquiries:
|
Sarah
Alspach
|
+1 202
715 1048
|
(Washington,
DC)
|
|
|
Sarah
Spencer
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Tom
Curry
|
+ 1 215
751 5419
|
(Philadelphia)
|
|
|
Gary
Davies
|
+44 (0)
20 8047 5503
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
|
|
|
|
Cautionary statement regarding forward-looking statements
GSK cautions investors that any
forward-looking statements or projections made by GSK, including
those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially
from those projected. Such factors include, but are not limited to,
those described under Item 3.D 'Risk factors' in the company's
Annual Report on Form 20-F for 2015.
|
|
Registered in England & Wales:
No. 3888792
|
|
|
|
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: December
13, 2016
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|